Aplitabart

Other Medications

Experimental

Not available 1 Clinical Trials

Description

Aplitabart (also known as IGM-8444) is an experimental medication being studied by IGM Biosciences. It is not currently approved for treating colorectal cancer (CRC) or any other condition. It was investigated in clinical trials, including a Phase 1 study (NCT04553692), which involved patients with various cancers, including CRC. In this trial, Aplitabart was tested alone and in combination with other cancer treatments, such as FOLFIRI (a chemotherapy regimen including 5-fluorouracil, leucovorin, and irinotecan) and bevacizumab (a targeted therapy). The goal of the Phase 1 trial was to determine the safety and how patients respond to Aplitabart, especially in patients whose cancer had come back or was resistant to standard treatments. The trial has been terminated.

Mechanism of Action

Aplitabart is designed to target specific proteins on the surface of certain cancer cells. It is a type of bispecific antibody, meaning it is engineered to bind to two different targets simultaneously. The specific targets and the exact way Aplitabart works are still being characterized in clinical trials. The goal is for Aplitabart to help the body's immune system recognize and attack cancer cells.

Side Effects

Because Aplitabart is an experimental drug and the clinical trials have been terminated Detailed information about its side effects is limited. Side effects observed in the Phase 1 trial (NCT04553692) would depend on the dose and whether it was given alone or with other treatments. Common side effects seen in early-phase cancer trials can include fatigue Nausea Infusion reactions And changes in blood counts. More specific side effects related to Aplitabart are still being evaluated.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04553692 Phase 1

Terminated

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

United States, Australia, France, South Korea, Spain

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.